ArticleScientific reports2025
Claudin-4 as a dual regulator of genome stability and immune evasion in high grade serous ovarian cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- p62/SQSTM1-TRAF6/RIP1 complexes activate NF-κB-mediated PD-L1 expression and promote T-cell apoptosis in MKN45 gastric cancer cells.Journal of gastrointestinal oncology · 2026Article
- Claudin-4 Overexpression Predicts Poor Survival and Platinum Resistance in Epithelial Ovarian Cancer: A Potential Biomarker for Clinical Decision-Making.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
High-grade serous carcinoma (HGSC) thrives in an immune-suppressive microenvironment marked by poor T-cell infiltration and blunted anti-tumor responses, driving immune evasion, tumor progression, and therapy resistance. Regulation of genomic instability, which restricts cytoplasmic DNA accumulation, is essential to prevent immune activation. Claudin-4, often overexpressed in HGSC, is strongly linked to therapy resistance and plays a key role in regulating initiation and resolution of genomic instability, shaping the tumor's potential ability to evade immune surveillance and withstand treatment; however, its role in immune evasion remains unclear. We used in vitro ovarian cancer models with stable claudin-4 overexpression and knockdown. In a humanized mouse model, ovarian tumors were treated with the claudin mimic peptide (CMP) and a PARP inhibitor. Tumor growth and immune infiltration were assessed by IVIS imaging and spectral flow cytometry. Mechanistic studies included autophagy flux and ISRE reporter assays, complemented by immunoblotting, flow cytometry, confocal microscopy, and bioinformatic analyses of public datasets. We identified a novel claudin-4-driven mechanism that promotes immune evasion in HGSC. Claudin-4 regulated type I interferon signaling through a close association with the small GTPase Rab7, modulating tumor-immune interactions. This was linked to TCR-zeta chain suppression in T cells in vivo-a hallmark of immune evasion. Dual targeting of claudin-4-expressing tumors with CMP and niraparib reshaped the tumor immune microenvironment, restoring TCR-zeta expression and promoting CD8 + T-cell infiltration, leading to improved anti-tumor efficacy of the PARP inhibitor niraparib. Our data show that claudin-4 orchestrates tumor immune evasion and survival, positioning it as a dual regulator of genome stability and immune escape, and highlighting it as a promising therapeutic target in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.